Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

BACKGROUND: Patients with advanced squamous-cell non–small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully h...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:N Engl J Med
Hlavní autoři: Brahmer, Julie, Reckamp, Karen L., Baas, Paul, Crinò, Lucio, Eberhardt, Wilfried E.E., Poddubskaya, Elena, Antonia, Scott, Pluzanski, Adam, Vokes, Everett E., Holgado, Esther, Waterhouse, David, Ready, Neal, Gainor, Justin, Frontera, Osvaldo Arén, Havel, Libor, Steins, Martin, Garassino, Marina C., Aerts, Joachim G., Domine, Manuel, Paz-Ares, Luis, Reck, Martin, Baudelet, Christine, Harbison, Christopher T., Lestini, Brian, Spigel, David R.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4681400/
https://ncbi.nlm.nih.gov/pubmed/26028407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1504627
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky